FeesSafety
Pluang+

Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Market News
19 Oct 2026, 13:00 WIB
Na
View Source
Bullish
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to better treatment response. This trial aims to confirm earlier positive phase 2 results showing significant symptom improvement. Topline results are expected by the end of 2026, potentially offering the first targeted therapy for over 1.5 million moderate to severe DED patients in the US with this genetic profile.

Oculis Holding AG's PREDICT-1 trial on Licaminlimab targets a genetic variant found in two-thirds of enrolled patients. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: out of 150 priced US health stocks, 79 rose and 65 fell. Notable movers include Acadia Healthcare Company Inc (ACHC) at USD 29.98 with a -5.34% change and a typical hold time of 8 days, Dyne Therapeutics Inc. (DYN) at USD 14.25 with a -5.25% change and a 3-day hold time, and Davita Inc (DVA) at USD 190.05 with a +5.17% change and a 115-day hold time.

More News

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms both demonstrate robust revenue growth driven by digital advertising and AI integration, with Alphabet focusing on search and cloud services, and Meta on social media engagement. Alphabet reported $471.1 billion revenue an...

Market News
Bullish
14 minutes ago
Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Coinbase Global and Mastercard represent two paths in finance: crypto infrastructure versus traditional payments. Coinbase's revenue is tied to volatile crypto trading, showing a 26.6% revenue decline and a net loss of $701.6 million in the past year...

Market News
Neutral
27 minutes ago
Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

On December 9, three major events will influence the stock market: the Federal Open Market Committee (FOMC) is expected to raise interest rates, Broadcom will report its earnings with a focus on AI semiconductor revenue, and Micron will begin a large...

Market News
Neutral
37 minutes ago
Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Realty Income, a large net-lease REIT with over 15,500 properties, faces headwinds from rising interest rates which increase borrowing costs and pressure profits. However, the company has a strong track record of increasing dividends for 32 years and...

Market News
Bullish
52 minutes ago
DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App